1. Home
  2. ASLE vs LYEL Comparison

ASLE vs LYEL Comparison

Compare ASLE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerSale Corporation

ASLE

AerSale Corporation

HOLD

Current Price

$5.87

Market Cap

309.5M

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$13.88

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASLE
LYEL
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
309.5M
320.1M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ASLE
LYEL
Price
$5.87
$13.88
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$7.00
$30.60
AVG Volume (30 Days)
382.5K
154.0K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
N/A
EPS
N/A
N/A
Revenue
$335,286,000.00
$36,000.00
Revenue This Year
$23.41
N/A
Revenue Next Year
$6.80
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.56
$10.49
52 Week High
$9.08
$45.00

Technical Indicators

Market Signals
Indicator
ASLE
LYEL
Relative Strength Index (RSI) 41.81 50.41
Support Level $5.56 $11.87
Resistance Level $6.77 $14.14
Average True Range (ATR) 0.23 0.88
MACD -0.06 0.10
Stochastic Oscillator 26.67 42.74

Price Performance

Historical Comparison
ASLE
LYEL

About ASLE AerSale Corporation

AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: